SIRT1 activating compounds (STACs) negatively regulate pancreatic cancer cell growth and viability through a SIRT1-lysosomal-dependent pathway

PURPOSE: Recent studies suggest that SIRT1 activating compounds (STACs) are a promising class of anti-cancer drugs, although their mechanism of action remains elusive. The main goal of this study is to determine the role of STACs as a potential therapy for pancreatic cancer. In addition, we also exp...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Chini, Claudia C.S., Netto, Jair M. E., Mondal, Gourish, Guerrico, Anatilde M Gonzalez, Nin, Veronica, Escande, Carlos, Sola-Penna, Mauro, Zhang, Jin-San, Billadeau, Daniel D., Chini, Eduardo N.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4867252/
https://ncbi.nlm.nih.gov/pubmed/26655844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1760
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares